| Recruiting | Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for NCT07405476 | Emory University | Phase 2 |
| Not Yet Recruiting | Family Communications After Genetic Testing NCT07143487 | Alliance for Clinical Trials in Oncology | N/A |
| Recruiting | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery NCT06780787 | City of Hope Medical Center | Phase 2 |
| Recruiting | Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE NCT06834126 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met NCT06575725 | City of Hope Medical Center | Phase 2 |
| Recruiting | Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Ca NCT06746012 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer NCT03594630 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side NCT05722288 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After NCT05610163 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Recruiting | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in L NCT05245786 | City of Hope Medical Center | EARLY_Phase 1 |
| Active Not Recruiting | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer NCT04929028 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta NCT05308446 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer NCT04751370 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer NCT05081024 | OHSU Knight Cancer Institute | — |
| Terminated | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) NCT04406857 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer NCT04703101 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S NCT04599140 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast NCT04362839 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr NCT03765736 | Academic and Community Cancer Research United | — |
| Completed | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca NCT04109924 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer NCT04104139 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer NCT03592641 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment NCT03516942 | ECOG-ACRIN Cancer Research Group | — |
| Recruiting | Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer NCT02107105 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer NCT02874885 | M.D. Anderson Cancer Center | — |